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Objectives: To explore the impact of market competition on pharmaceutical pric-
ing, and to further investigate the determinants of pharmaceutical price in Chinese 
pharmaceutical market. MethOds: Anti-infective pharmaceutical data were 
extracted from inpatient claims in Tianjin Urban Employee Basic Medical Insurance 
(UEBMI) database from 2006 to 2010. Based on product-quarter data, a quasi-hedonic 
regression model was used to estimate the impact of market competition, which 
is defined by generic competition (the number of manufacturers within the same 
generic market) and therapeutic competition (the number of molecules in the ATC3 
therapeutic category). The inputs to our model were specific attributes of the products 
and manufacturers, with the exception of competition variables. Defined daily dose 
(DDD) was used as the standard quantity unit and the price per DDD was used as the 
price unit. Results: Our results indicated that pharmaceutical prices were inversely 
related to the number of generic competitors, but positively related to the number 
of therapeutic competitors. The prices of patent drugs and the off-patent drugs from 
original manufacturer were significantly higher than the prices of generic drugs. 
We also found the positive relationship between DDD and price, and the negative 
relationship between pack size and price which implied that manufacturers com-
pete on volume discounts on large pack size. In addition, product age was inversely 
related to product price. In terms of manufacturers’ attributes, the results suggested 
that the prices of products imported by the foreign manufacturers and produced by 
joint-venture firms were higher than those of products from local manufacturers, and 
the prices of products from domestic 100 top-selling manufacturers were lower than 
those of products from non-top 100 local manufacturers. cOnclusiOns: Generic 
market competition still plays an important role in determination of regulated phar-
maceutical prices in China. The drug attributes, manufacturers’ attributes and market 
competition are jointly determined pharmaceutical price.
PHP7
Price comParison Between tHe essential and non-essential  
anti-infective medicines among national reimBursement  
drug list in cHina
Ma F.F., Wu J., Zhao M.Y.
Tianjin University, Tianjin, China
Objectives: To compare the price changes of the essential and the non-essential 
anti-infective medicines in Tianjin, China using index method. MethOds: Data were 
extracted from inpatient claims in Urban Employee Basic Medical Insurance data-
base of Tianjin, China, from 2006 to 2010. Price indices were measured by Fisher and 
chained Fisher index formulas by quarter. The quantity weight unit was defined daily 
dose (DDD) and the price unit was the price per DDD. Price indices were calculated 
both at molecule level (defined by active ingredient) and product level (defined by 
molecule, strength, preparation, and manufacturer). Results: The data contained 
41 molecules and 786 products among the essential anti-infective medicines, and 81 
molecules and 636 products among the non-essential anti-infective medicines. For 
the essential anti-infective medicines, the price index decreased to 0.90 (in chained 
Fisher index at molecule level) from 2006 Q1 to 2010 Q4, and the price index for the 
non-essential anti-infective medicines decreased to 0.73 (in chained Fisher index 
at molecule level) during the same period. For the essential and non-essential anti-
infective, the results of chained Fisher and unchained counterparts were similar 
(10% vs. 10% for the essential and 28% vs. 27% for the non-essential at molecule 
level). The price indices at molecule level decreased slower than the counterparts at 
product level (10% vs. 24% for the essential and 27% vs. 30% for the non-essential in 
chained Fisher index). cOnclusiOns: The price of the essential and non-essential 
anti-infective medicines among national reimbursement drug list had decreased in 
Tianjin, China, but the price of the essential anti-infective medicines decreased slower 
than the non-essential anti-infective medicines.
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Objectives: To assess the impact of drug policy on improving access to essential 
medicines in Delhi MethOds: The quantity of drugs procured from the Essential 
Drugs List (EDL) and outside the EDL; money spent on these; changes in stock out 
days for the key drugs. The implementation strategy includes elements of drug 
policy like use of EDL & STG, improved procurement system, training on drugs 
management & rational use of drugs. Retrospective data collected from stock reg-
isters. The data for two years before (1993-1994, 1994-1995) and two years after 
(2000-2001, 2001-2002) the drug policy was assessed. Data collected from two large 
public sector hospitals in Delhi that serve a large section of the population through 
convenient purposive sampling method. Results: After the implementation of 
the drug policy, the availability of drugs increased by 25% in the large and 98% in 
the medium hospital. The drugs procured from the EDL increased from 62% to 78% 
in the large and 74% to 87% in the medium hospital. Of the total expenditure, the 
money spent on essential drugs increased from 73% to 85% in the large and 87% to 
93% in the medium hospital, whereas money spent on nonessential drugs decreased 
from 27% to 15% in the large and 13% to 7% in the medium hospital. The average 
number of stock out days for key dugs decreased from 33 to 16 days in the large 
and from 143 days to 33 days in the medium hospital. The utilization pattern of 
health services by patients increased by 8% in the large and by 35% in the medium 
hospital. cOnclusiOns: The implementation of the drug policy in the state of 
Delhi increased availability of essential drugs. This kind of intervention can serve 
as a model for improving access to medicines by implementing an effective drug.
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Objectives: Diagnosis related groups (DRG) like financing method was introduced in 
Hungary in 1993 for acute care hospital reimbursement. Due to the increased activity 
of the hospitals, an upper ceiling, the so called performance volume limit (PVL) was 
introduced in acute care hospital financing in 2004. The aim of our study was to ana-
lyze the effect of performance volume limit on DRG based hospital financing on the 
example of a Hungarian tertiary teaching hospital, the Clinical Centre of the University 
of Pécs. MethOds: Data derived from the financial database of the National Health 
Insurance Fund Administration, the only health care financing agency in Hungary. 
We analyzed the proportion of hospital activity over the performance volume limit 
ceiling. We calculated the proportion of hospital activity over that ceiling measured by 
DRG cost-weights. The period 2004-2013 was involved into the study. Results: The 
annual number of patients varied between 72671 (2007) and 82509 (2009) at the Clinical 
Centre of the University of Pécs. During the same period the annual performance 
volume limit for DRG costweigths varied between 97784 and 116970. However due to 
the regulation of the upper ceiling of hospitals’ activity, 3.0 % (2007) to 14.9 % (2009) of 
that activity has not been reimbursed to the Clinical Centre. The average loss of reim-
bursement due to performance volume limit was 7.2 % of annual revenues between 
2004-2013. cOnclusiOns: The introduction of performance volume limit into the 
DRG based hospital financing resulted in a partial loss of hospitals’ revenues. Despite 
of in PVL regulation, the Clinical Centre of the University of Pécs did not reduced its 
output, thus the annual number of patients did not declined in this hospital.
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Objectives: The metabolic syndrome (MS), a combination of metabolic abnormali-
ties including obesity, diabetes, dyslipidemia and hypertension is associated with 
an increased risk of coronary heart disease and stroke. Complementary medicines 
including herbs like Turmeric and Black seeds (Nigella sativa) can be used to pre-
vent or as an adjuvant to control MS with fewer side-effects, better acceptability 
and cost effectiveness. This study determines if the co-administration of Turmeric 
potentiates the beneficial effects of black seeds on MS in rats. MethOds: Black seeds 
and Turmeric alone and in combination at different dosages were administered to 
fructose-fed rats. Blood pressure, fasting sugar and lipid profile were measured 
before and after 3 and 6 weeks of treatment. Serum insulin and endothelial func-
tion were determined at 6 weeks of intervention Results: Black seeds at the dose 
of 0.6 g/kg prevented hypertension at week 3 of intervention, while at 6 weeks it 
prevented hypertension, hyperglycemia, dyslipidemia and endothelial dysfunction. 
Turmeric at 3 g/kg dose prevented dyslipidemia but not hypertension. The combi-
nation of 0.3 g/kg Black seeds and 1.5 g/kg Turmeric prevented hypertension and 
hypertriglyceridemia at week 3 but provided a wide coverage at 6 weeks including in 
hypertension, hyperglycemia, dyslipidemia, hyperinsulinemia and endothelial dys-
function. cOnclusiOns: This study showed that co-administration of Turmeric and 
Black seeds resulted in enhanced efficacy in correcting metabolic syndrome when 
compared with each component used alone, while the reduced dose of individual 
component when used in combination is likely to reduce the side-effects.
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Objectives: Though almonds are shown to be effective in cardiovascular disorders 
(CVDs), but there is limited information on the possible mode of action. This study 
aimed at exploring, in multiple rat models, the pharmacological basis for the medici-
nal use of almonds in CVDs. MethOds: Tyloxapol, high-fat diet (HFD) and fructose 
models were used. Group 1 in each study was normal control and group 2 and 3 were 
diseased groups. Almonds were given for four weeks to group 3 of each study, after 
which blood was collected for biochemical estimations. Liver from rats of tyloxapol 
study and thoracic aorta from rats of HFD study were isolated for enzyme assays and 
vascular reactivity. Results: Almonds supplementation significantly (p < 0.05) pre-
vented hyperlipidemia in all the three rat models. In tyloxapol-induced hyperlipidemia 
model, almond supplementation inhibited HMG-CoA activity. It also improved lipid 
profile and prevented HFD-induced increase in serum biomarkers of liver dysfunc-
tion (amino-transferases) and endothelial dysfunction (uric acid, phosphorus, alkaline 
phosphatase and gamma glutamyl transferase) as well as restored endothelial reac-
tivity. Almonds also demoted the HFD-induced inhibition of endothelial nitric oxide 
synthase enzyme, thereby, promoting serum nitric oxide release. In the fiber-free while 
flour with fructose model, improvement in serum HDL was observed, in addition to 
improvement in other markers of lipid abnormality. cOnclusiOns: Almond sup-
plementation demonstrated cardio-protection and antidyslipidemic effect mediated 
through multiple pathways including inhibition of cholesterol synthesis and restora-
tion of hepatic and endothelial function, while the use of multiple animal models aided 
in gaining insights on some of the possible mechanism of actions.
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